BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent

Dual inhibition of autophagy and the AKT pathway in prostate cancer

(2013) Francois Lamoureux et al.   Autophagy

Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells

(2013) Hyeon-Ok Jin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Chromatin-Bound IκBα Regulates a Subset of Polycomb Target Genes in Differentiation and Cancer

(2013) María Carmen Mulero et al.   CANCER CELL

RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation

(2013) Matthew Holderfield et al.   CANCER CELL

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

(2013) Georgia Hatzivassiliou et al.   NATURE

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study

(2012) Kazuhito Sasaki et al.   ANTI-CANCER DRUGS

KrasG12D-Induced IKK2/β/NF-κB Activation by IL-1α and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma

(2012) Jianhua Ling et al.   CANCER CELL

TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

(2012) Anurag Singh et al.   CELL

Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363

(2012) F. Lamoureux et al.   CLINICAL CANCER RESEARCH

Ubiquitination in signaling to and activation of IKK

(2012) Zhijian J. Chen   IMMUNOLOGICAL REVIEWS

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas

(2012) H J Maier et al.   ONCOGENE

A Truncated Form of IKKα Is Responsible for Specific Nuclear IKK Activity in Colorectal Cancer

(2012) Pol Margalef et al.   Cell Reports

TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer

(2011) Daniel T. Starczynowski et al.   JOURNAL OF CLINICAL INVESTIGATION

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Wnt Signaling Requires Sequestration of Glycogen Synthase Kinase 3 inside Multivesicular Endosomes

(2010) Vincent F. Taelman et al.   CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

(2009) Etienne Meylan et al.   NATURE

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

The Signaling Adaptor p62 Is an Important NF-κB Mediator in Tumorigenesis

(2008) Angeles Duran et al.   CANCER CELL

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE